New opportunity: Apply to join our Biotech & Health Extension accelerator!
What has happened so far? Revolutionizing the aging industry, brain cell replacements, news in health extension trials and much more.
Do you work on extending human healthspan? Make sure you apply to our virtual accelerator. Topics of interest include regenerative medicine, targeted brain therapies, biomarker comparisons, combination therapies, health data gathering platforms.
We asked Sonia Arrison, 100 Plus Capital, and our Biotech Group. Lecture summary and recording can be found here.
Key points:
Coalition-building across actors on grand issues, such as aging as disease, stronger advocacy on COVID-19 and aging connections, focus on biomarker standardization and validation, exploring novel funding structures to pool early-stage investments, and much more.
We asked Sonia Arrison – 100 Plus Capital, Mike West – AgeX and Karl Pfleger – Aging Biotech. Lecture summary and recording can be found here.
Key points:
Sonia Arrison on regeneration plus focus on brain aging, enabled by a general uptake in focus on brain research.
Karl Pfleger on better “debuggers for biological blackboxes”, trialing combinations of therapies and aiming for robust mouse regeneration.
Mike West on treatments of chronic degenerative diseases associated with aging and the potential of partial reprogramming for induced tissue regeneration.
We asked Irina Conboy, UC Berkeley. Lecture summary and recording can be found here.
Key points:
Parabiosis works because of old blood dilution, young blood is not the medicine.
Old plasma dilution may be safer and more robust for rejuvenation than all other current approaches, already approved by FDA.
Neutral blood exchange has senolytic or senomorphic properties, so in theory, you do not need to use senolytics if you use neutral blood exchange.
We asked Brian Kennedy – Buck Institute, Joris Deelen – Max Planck Institute for Ageing, Lynne Cox – Oxford University Lecture summary and recording can be found here.
Key points:
Brian Kennedy on understanding the connections between hallmarks of aging and funding more small molecule research.
Lynne Cox on multi-targeted approaches, instead of 1 target = 1 drug, move to x targets = 1 drug via function-first phenotypic drug screening.
Joris Deelen on aging marker translatability: compare aging biomarkers with existing markers such as cholesterol to see if they can be replaced in the clinic and bringing cost down to test on larger scales.
We asked Jean Hebert from the Albert Einstein School of Medicine. Lecture summary and recording can be found here.
Key points:
Current approaches will get us to live slightly longer and healthier but we won’t defeat aging. Almost every part of the body has been successfully replaced over the years, apart from the brain.
Brain tissue replacement is a necessary strategy for the long-term defeat of aging. The brain should be replaceable progressively via brain cell replacements without losing our identity.
Jean covers the history of the field and research so far to make a case for pursuing this approach further based on the available positive data. She also introduces a roadmap plus experiment which is open for funding.
We asked Dr. James Kirkland from the Mayo Clinic. Lecture summary and recording can be found here.
Key points:
A comprehensive overview of the current state of research about senescent cells and senolytic clinical trials. How do senescent cells become senescent? How do they work? what kind of functions do they play?
Summary of 15 clinical trials that are currently testing senolytics on different indications, plus explanations and motivations behind the trials and what are the studies already in the process of finding.
Discussion includes an exact definition of senescence, whether low carb diet is mirroring senloytics, hit and run vs. continuous dosing of senolytics, wound healing, future studies and concerns about experimentation.
| So remember to send in your health extension application, and to stay tuned for future meetings! |
For those of you thinking you might sell some of your crypto this year- You can offset a lot of your taxes by donating some of your crypto and getting a double tax deduction. When you donate any asset, like cryptocoins, that have gone way up, you not only don’t have to pay taxes on the gain on those coins, you can deduct the full value of the coins from your other income too. Never, sell coins and donate the cash, support us directly with the coins instead <3.
